Overview

The Dr. Stephen A. Harrison Patient Advocacy Fellowship Program is a pioneering initiative designed to elevate the role of patient advocates in MASH (Metabolic Dysfunction-Associated Steatohepatitis) and steatotic liver disease (SLD) research, drug and diagnostic development, and policy discussions. This annual fellowship empowers up to 20 patient advocates by providing financial support, education, and access to key scientific and policy forums where they can contribute meaningfully to shaping the future of liver disease care.

Through a guided learning experience and engagement with leading researchers, patient advocates, policymakers, and industry stakeholders, fellows will develop the knowledge, leadership skills, and networks necessary to drive patient-centered innovation in liver disease research.

Why This Program?

Despite significant advancements in MASH research, the patient voice remains underrepresented in clinical trial design, regulatory decision-making, and policy development. Many patients lack the resources, training, and access needed to actively participate in shaping research and care models.

This fellowship was created to:

• Empower patient advocates with clinical trials literacy and policy knowledge.
• Bridge the gap between patients, researchers, and industry leaders.
• Ensure treatments align with the real-world experiences of those living with MASH and other types of steatotic liver disease.
• Support participation in national and global conferences, ensuring that patient perspectives inform discussions on research and drug development.

By investing in patient advocacy leadership, this program contributes to more inclusive, effective, and patient-driven advancements in liver health.